Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$83,372.00-2.51%ETH$2,574.91-4.55%GOLD$4,130.50-0.25%OIL$89.24+1.09%
Smart Investors Daily
SID Premium
QN

NASDAQ · QNTM

Quantum BioPharma Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

$3.09

Up+$0.06 (+1.78%)

Updated Oct 8, 2026, 1:27 AM

SID Score

4.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
37.41M
P/E ratio
-1.1
Dividend yield
0.00%
52-week range
$2.07 – $18.87
Volume
627.08K
Avg. volume
120.46K

Price performance · QNTM

QNTM price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

QNTM closed at $3.09 after 20 trading sessions, down 13.69% for the selected period.

Last close
$3.09
Period change
-13.69%
Period low
$3.09
Period high
$4.00
Daily close
View OHLC price history
QNTM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$3.34$3.39$3.05$3.09627.08K
Oct 5, 2026$3.40$3.49$3.25$3.27246.76K
Oct 2, 2026$3.38$3.47$3.32$3.4479.31K
Oct 1, 2026$3.56$3.6628$3.40$3.42582.71K
Sep 30, 2026$3.72$3.80$3.53$3.60114.06K
Sep 29, 2026$3.95$3.9567$3.7065$3.82120.2K
Sep 28, 2026$3.86$3.99$3.6724$3.96140.27K
Sep 25, 2026$4.00$4.00$3.80$3.85193.38K
Sep 24, 2026$4.00$4.30$3.8226$4.00564.46K
Sep 23, 2026$3.65$4.34$3.65$3.88645.26K
Sep 22, 2026$3.66$3.90$3.60$3.70193.81K
Sep 21, 2026$3.65$3.82$3.52$3.6178.61K
Sep 18, 2026$3.69$3.83$3.615$3.6696.45K
Sep 17, 2026$3.63$3.88$3.63$3.72191.75K
Sep 16, 2026$3.48$3.69$3.3863$3.65200.17K
Sep 15, 2026$3.43$3.50$3.25$3.46103.6K
Sep 14, 2026$3.22$3.59$3.135$3.46173.4K
Sep 11, 2026$3.32$3.3899$3.20$3.20200.79K
Sep 10, 2026$3.54$3.60$3.0815$3.29239.08K
Sep 9, 2026$3.34$3.7387$3.33$3.58445.64K

Latest QNTM news

The latest Smart Investors Daily articles mentioning QNTM.

Stock researchCompany · Overview

QNTM research

Overview

Company profile and research snapshot.

Company profile

Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$33.28
Implied upside
—
Analysts
7
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

AUSTIN, Texas, Sept. 30, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancem

Yahoo · Sep 24, 2026

Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO

TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) (“Quantum BioPharma”), today announced its licensee – Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzd™ (“unbuzzd”) — the scientifically-proven and game-changing beverage proven to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms, is pleased to announce the appointment of Mr. Michael Zapolin (“Zappy”) as CEO. This marks a pivotal milestone

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By